PLAT and angioedema: As studies continue to demonstrate the efficacy of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke, the exclusion criteria continue to narrow, and the time-window continues to increase.1–3 The most dreaded adverse effect of tPA, hemorrhagic conversion of an ischemic stroke, is well known and well published.3 However, as an increasing number of patients are receiving tPA worldwide another unusual and potentially life-threatening adverse effect of tPA is becoming more common, angioedema.